2017 Fiscal Year Final Research Report
The impact of hemoxygenase-1 (HO-1) on the treatment outocome after bone marrow transplantation and the possibility of HO-1 as a new therapeutic target
| Project/Area Number |
15K08643
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
谷内江 昭宏 金沢大学, 医学系, 教授 (40210281)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 造血幹細胞移植 / 移植後合併症 / ヘムオキシゲナーゼ-１(HO-1) / 一塩基置換 / Fc receptor-like 3遺伝子 / タクロリムス（ＦＫ506） / 遺伝子組換えトロンボモジュリン |
|---|
| Outline of Final Research Achievements |
We investigated the impact of the Fc receptor-like 3 variant（s3761959） on transplantation outcomes in a cohort of 1029 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. We revealed that the recipient T/T genotype was associated with significantly better overall survival rates and a lower incidence of treatment-related death than the recipient C/C or C/T genotype.
Tacrolimus (FK506) calcineurin inhibitor is an effective immunosuppressant which is essential to prevent allograft rejection. We showed that FK506 impaired the function of coagulation and fibrinolytic systems and permeability in the human umbilical endothelial cells in vitro. Moreover, pre-treatment of recombinant thrombomodulin prevented these endothelial dysfunction.
|
| Free Research Field |
血栓止血
|
